SCHEMBL8043533

SCHEMBL8043533

Cc1cccc2c(CCNc3c(F)cc(Nc4ccncc4)cc3F)c[nH]c12

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTR2A P28223 1/20 0.47
MAPT P10636 2/20 0.46
SMN1; SMN2 Q16637 1/20 0.46
NPSR1 Q6W5P4 1/20 0.46
SOS2 Q07890 1/20 0.38
SPR P35270 1/20 0.38
MPO P05164 4/20 0.38
SLC6A4 P31645 4/20 0.38
ADRB3 P13945 1/20 0.38
KMT2A Q03164 2/20 0.36
PCSK9 Q8NBP7 1/20 0.36
MEN1 O00255 1/20 0.36
POLB P06746 1/20 0.35
SLC2A1 P11166 1/20 0.35
RAD52 P43351 1/20 0.35
NR3C1 P04150 2/20 0.35
PGR P06401 1/20 0.35
NR3C2 P08235 1/20 0.35
GPR84 Q9NQS5 1/20 0.34
AR P10275 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8075490 0.88 HTR2A (0.51) HTR2AMAPTSMN1; SMN2NPSR1SOS2
SCHEMBL8040347 0.88 HTR2A (0.44) HTR2AMAPTSMN1; SMN2NPSR1SOS2
SCHEMBL8042882 0.86 HTR2A (0.42) HTR2AMAPTSMN1; SMN2NPSR1SOS2
SCHEMBL8043532 0.83 KMT2A (0.54) HTR2ASPRKMT2AMEN1POLB
SCHEMBL8041131 0.78 HTR2A (0.41) HTR2AMAPTSMN1; SMN2NPSR1SOS2
SCHEMBL13130727 0.77 KMT2A (0.46) HTR2ASPRMPOSLC6A4KMT2A
SCHEMBL13130717 0.77 HTR2A (0.37) HTR2AMAPTSMN1; SMN2NPSR1SOS2
SCHEMBL12811043 0.77 KMT2A (0.54) HTR2AMAPTSPRKMT2AMEN1
SCHEMBL8048232 0.76 HTR2A (0.51) HTR2AMAPTKMT2AMEN1CYP3A4
SCHEMBL12811037 0.76 ALDH1A1 (0.37) MAPTSPRMPOSLC6A4KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11583524-B2 Inhibitors of the interaction between MDM2 and P53 JANSSEN PHARMACEUTICA NV (BE) 2023-02-21 US disclosed
US-20200121667-A1 Inhibitors Of The Interaction Between MDM2 And P53 JANSSEN PHARMACEUTICA NV (BE) 2020-04-23 US disclosed
US-20170112818-A1 INHIBITORS OF THE INTERACTION BETWEEN MDM2 AND P53 JANSSEN PHARMACEUTICA NV (BE) 2017-04-27 US disclosed
US-20170112818-A1 INHIBITORS OF THE INTERACTION BETWEEN MDM2 AND P53 JANSSEN PHARMACEUTICA NV (BE) 2017-04-27 US disclosed
US-9573933-B2 Inhibitors of the interaction between MDM2 and P53 JANSSEN PHARMACEUTICA NV (BE) 2017-02-21 US disclosed
US-9573933-B2 Inhibitors of the interaction between MDM2 and P53 JANSSEN PHARMACEUTICA NV (BE) 2017-02-21 US disclosed
US-20100240637-A1 Inhibitors of the Interaction Between MDM2 and P53 JANSSEN PHARMACEUTICAL NV (BE) 2010-09-23 US disclosed
US-20100240637-A1 Inhibitors of the Interaction Between MDM2 and P53 JANSSEN PHARMACEUTICAL NV (BE) 2010-09-23 US disclosed
WO-2009037308-A1 INHIBITORS OF THE INTERACTION BETWEEN MDM2 AND P53 JANSSEN PHARMACEUTICA NV (BE) 2009-03-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100240637-A1 Inhibitors of the Interaction Between MDM2 and P53 TP53, MDM2, TP53BP1 HTR2A 3374/4885MAPT 1187/4885SMN1; SMN2 3777/4885
US-20170112818-A1 INHIBITORS OF THE INTERACTION BETWEEN MDM2 AND P53 TP53, MDM2, TP53BP1 HTR2A 3374/4885MAPT 1187/4885SMN1; SMN2 3777/4885
US-11583524-B2 Inhibitors of the interaction between MDM2 and P53 TP53, MDM2, TP53BP1 HTR2A 3374/4885MAPT 1187/4885SMN1; SMN2 3777/4885
US-20200121667-A1 Inhibitors Of The Interaction Between MDM2 And P53 TP53, MDM2, TP53BP1 HTR2A 3587/4885MAPT 1012/4885SMN1; SMN2 3697/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.